Waters reported a non-generally accepted accounting principles (GAAP) adjusted free cash flow of $155 million, down from $175 million after funding $37 million in capital expenditures. Year to date, free cash flow increased by 17% to $348 million, the company reported.

On a GAAP basis, the company reported a diluted earnings per share of $2.69 in the second quarter, up from $1.98 for the same period in 2020. Non-GAAP earnings per share were $2.60 year over year from $2.10.

In its earnings report, Waters noted broad commercial momentum in pharmaceutical and industrial end markets, which were up by 34% and 31%, respectively, in the second quarter.

Waters is anticipating a sales growth rate of 13% to 15% for 2021 in constant currency.

Waters expands collaboration with BTI of Singapore
Waters has expanded its existing collaboration with the Bioprocessing Technology Institute (BTI), a research entity in Singapore's Agency for Science,...

Waters launches Arc Premier liquid chromatography
Lab equipment supplier Waters has unveiled the Arc Premier system, a liquid chromatography system aimed at increasing precision and certainty in chromatography...

Waters debuts mass spectrometer with MRT technology
Waters has introduced its next-generation Select Series multireflecting time-of-flight (MRT) mass spectrometer. The new system is designed to provide...

Waters reports 30% sales increase in Q1
Lab equipment supplier Waters reported significant sales growth during the first quarter of 2021.